TELA Bio’s Restella Reconstructive BioScaffolds Receives FDA’s 510(k) Clearance for Reconstructive Surgery

 TELA Bio’s Restella Reconstructive BioScaffolds Receives FDA’s 510(k) Clearance for Reconstructive Surgery

TELA Bio’s Restella Reconstructive BioScaffolds Receives FDA’s 510(k) Clearance for Reconstructive Surgery

Shots:

  • The US FDA granted 510(k) clearance to Restella reconstructive bioscaffolds as it reinforced soft tissue in patients requiring soft tissue repair or reinforced during plastic or reconstructive procedures
  • TELA Bio technology is based on interwoven polymer with a layer of biologic tissue in lockstitch pattern Additionally, TELA Bio has a strong clinical portfolio including OviTex Reinforced BioScaffolds for hernia repair and abdominal wall reconstructions and is commercialized in the US
  • Restella reconstructive bioscaffold is a device intended for one-time use only and is highly permeable with controlled stretch to support surgical techniques. TELA Bio plans to form resorbable and permanent polymer versions of Restella reconstructive bioscaffolds in different sizes & shapes

Click here to read full press release/ article | Ref: PRNewswire | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post